Amyloidosis News - March 2021

Accelerated Approval Granted for Newly Diagnosed Light Chain Amyloidosis Treatment

The ANDROMEDA study revealed a significant hematologic complete response rate in patients with newly diagnosed light chain amyloidosis treated with daratumumab plus hyaluronidase human-fihj. Read More ›

Highlighting Misdiagnosis: Technetium-Pyrophosphate Cardiac Scintigraphy Shows Limits of Transthyretin Amyloid Imaging

Misdiagnosis

Other amyloid subtypes may also cause myocardial pyrophosphate radiotracer uptake, highlighting the need for caution when using noninvasive diagnostic approaches. Read More ›

Recognizing Potential Clinical Markers of Hereditary Transthyretin Amyloidosis for Early Diagnosis

Hereditary ATTR

Clinicians need to be aware of potential signals of hereditary transthyretin amyloidosis that most commonly present in the year before diagnosis. Read More ›

Tracing the Journey Among Patients with Tc-Pyrophosphate–Positive Transthyretin Cardiac Amyloidosis

Early Diagnosis

Clinical signals and features of positive PYP transthyretin cardiac amyloidosis highlight the need for early diagnosis. Read More ›

Prognostic Predictors Based on Echocardiographic Phenotype of Transthyretin Cardia Amyloidosis

Clinical Management

The presence of severe aortic stenosis in the context of transthyretin cardiac amyloidosis is associated with a dramatic reduction in patient survival. Read More ›

Amyloidosis News - March 2021

Top Trending Articles